Crossmark

Pyrotinib as a salvage treatment for patients with HER-2 positive advanced lung adenocarcinoma after the progression of afatinib treatment

Published Online: 2024-05-25

Authors

Xu, Manyi

Wang, Yanhua

Shao, Keda

Hao, Yue https://orcid.org/0000-0002-4725-6084
Song, Zhengbo
Funding

Funding for this research was provided by:

Medical Scientific Research Foundation of Zhejiang Province (No.2022KY653)
License Information

Text and Data Mining valid from 2024-05-25

Version of Record valid from 2024-05-25
More Information

Article History

Received: 9 February 2024

Accepted: 25 March 2024

First Online: 25 May 2024

Declarations

:

: All authors declare no conflict of interest.

: Approval of the study protocol was obtained from Zhejiang Cancer Hospital Institutional Review Board Committee (approval number: IRB-2023–377). Individual consent for this retrospective analysis was waived.

: Not applicable.

: Individual consent for analysis was waived.

Document is current